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Abstract 
 
Backgroung/Aim. Since combining conventional drugs 
with herbal medicinal products is in current research focus 
and possible of great interest as therapy improvement way, 
the aim of this study was to determine the effects of well-
established antiatherosclerotic drug atorvastatin (CAS num-
ber 134523-00-5) and commercially available artichoke leaf 
tincture (ALTINC), used as combined therapy, as well as to 
compare effects of these two treatments separately. Meth-
ods. Experimental animals were divided into five groups: 
the group I (the control group of rats fed with standard diet 
during 11 weeks), and the remaining 4 groups of rats (II, III, 
IV and V) fed with standard diet during the first week and 
then with hypercholesterolemic diet during the next 10 
weeks. The group II of rats were left without treatment, 
while in the groups III, IV and V were rats treated per os 
with atorvastatin (1.15 mg/kg body wright − b.w.), 
ALTINC (0.1 mL/kg b.w.) and their combination in same 
doses, respectively, for the last six weeks. Results. The cho-
lesterol rich diet led to pronounced hyperlipidemia which 
could not be overcame with the therapy. However, the ther-
apy showed positive effects on abdominal aorta wall thick-
ness and parameters of oxidative stress (malondialdehyde − 
MDA, proxidative-antioxidative balance − PAB) and anti-
oxidative protection (reduced glutathione − GSH, paraox-
anase 1 − PON1, superoxide dismutase − SODA SH 
groups), especially ALTINC was successful in oxidative 
status improvement. Conclusion. Separate treatments 
comparison showed that artichoke leaf tincture is very po-
tent antioxidant with beneficial effects in early stages of 
atherosclerosis. Since atorvastatin and constituents of 
ALTINC probably have different mechanisms of action, 
simultaneous use of both therapies could be beneficial but 
should be further investigated since our results showed that 
ALTINC is less effective when used in combination with 
atorvastatin. 
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Apstrakt 
 
Uvod/Cilj. Savremena istraživanja sve više se okreću mo-
gućnosti kombinovanja konvencionalne terapije sa biljnim 
lekovitim proizvodima. Cilj ovog istraživanja bio je praćenje 
efekata atorvastatina (CAS broj 134523-00-5), poznatog leka 
koji se koristi u terapiji hiperlipidemije, i tinkture lista arti-
čoke primenjenih pojedinačno, kao i u obliku kombinovane 
terapije. Metode. Eksperimentalne životinje bile su podel-
jene u pet grupa: grupa I bila je kontrolna i činili su je pacovi 
hranjeni standardnom hranom za glodare tokom 11 nedelja, 
dok su preostale četiri grupe (II–V) činili pacovi koji su 
hranjeni standardnom hranom tokom prve nedelje, a potom 
u narednih 10 hranom bogatom holesterolom. Grupa II nije 
dobijala nikakav tretman, dok su III, IV i V posle 4. nedelje 
od početka uzimanja hrane bogate holesterolom, tokom 
narednih šest nedelja tretirane per os, redom: atorvastatinom 
u dozi od 1,15 mg/kg, tinkturom artičoke u dozi od 0,1 
mL/kg i njihovom kombinacijom u istim dozama. Rezul-
tati. Hrana bogata holesterolom izazvala je uznapredovalu 
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hiperholesterolemiju na koju terapija nije značajno delovala. 
Terapija je pokazala povoljan efekat na debljinu zida trbušne 
aorte, parametre oksidativnog stresa (malondialdehid − 
MDA, prooksidativni-antioksidativni balans − PAB) i anti-
oksidativne zaštite (redukovani glutation − GSH, SH grupe, 
paraoksonazu1 − PON1, superoksid dismutazu − SOD). 
Tinktura lista artičoke pokazala se najboljom u poboljšanju 
oksidativnog statusa. Zaključak. Poređenje pojedinačne 
terapije pokazalo je da tinktura lista artičoke ima jako anti-
oksidativno dejstvo i pokazuje povoljne efekte u početnim 
fazama aterosklerotskog procesa. S obzirom na to da ator-
vastatin i komponente tinkture lista artičoke verovatno de-
luju različitim mehanizmima, kombinovana primena može 
imati povoljne efekte, ali se mora dodatno ispitati jer dobi-
jeni rezultati ukazuju da je tinktura lista artičoke manje efi-
kasan kada se primenjuje zajedno sa atorvastatinom. 
 
Ključne reči: 
cynara scolimus; atorvastatin kalcijum; ateroskleroza; 
stres, oksidativni; pacovi; lečenje, ishod. 
 
Introduction 
Hyperlipidemia with plasma-elevated concentrations of 
cholesterol and low density cholesterol (LDL-C) is conside-
red to be the cause of cardiovascular disease. Treatment of 
hyperlipidemia needs diet control, exercise and using lipid-
lowering compounds such as drugs and diet. 
The 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) re-
ductase (EC 1.1.1.88) inhibitors (statins) have emerged as 
the most important class of lipid-lowering agents. Through 
inhibition of HMG-CoA reductase, they restrict the rate-
limiting step of cholesterol synthesis resulting in up-
regulation of low density lipopotein (LDL) receptors on the 
cell membrane and reduction of atherogenic LDL 
consequences. Several clinical trials have demonstrated the 
beneficial effects of statins in cardiovascular disorders, 
extending beyond their effects on cholesterol level, in 
primary and secondary prevention settings 1, 2. As a result, 
nowadays statins represent one of the most powerful agents 
for the treatment of cardiovascular events 3. Statins also have 
many cholesterol-independent (pleiotropic) beneficial effects 
such as their antioxidative activity 1, 4, 5. 
Although the side effects of statins are relatively low, 
they can cause rhabdomyolysis in rare cases 6. Therefore, re-
search to identify natural agents with lipid-lowering proper-
ties and with less or no adverse effects, especially medicinal 
plants, is warranted.  
Artichoke (Cynara scolymus L.) is a plant which is 
widely grown in Mediterranean countries. Leaves of this plant 
are rich in antioxidant constituents. It contains many different 
polyphenolic compounds such as cynarin, chlorogenic acid, lu-
teolin, apigenin 7, 8. Different types of artichoke leaf extract 
were reported to have a cholesterol-reducing effect on 
hypercholesterolemic subjects 9, 10. In addition, in vitro studies 
show that artichoke extract decreases the production of reacti-
ve oxygen species, oxidation of low-density lipoproteins and 
lipid peroxidation 11, 12. 
It is not unusual that patients on statin therapy 
concomitantly take herbal medicinal product (e.g. extracts of ar-
tichoke leaf prodacts or another) known for its antioxidant pro-
perties, therefore it is important to investigate any possible 
synergistic or opposite action of these treatments. Comparing 
antioxidant properties of these two therapies can give answer the 
question if it is reasonable to suggest artichoke leaf product usa-
ge in the beginning stages of atherosclerosis.  
Methods 
Diets, chemicals and herbal product 
In this experiment we used normal, commercial rat 
chow diet and special atherogenic diet prepared in our 
laboratory by adding cholesterol, sodium cholate and 
sunflower oil to commercial diet 13. Cholesterol and sodium 
cholate hydrate were purchased from Sigma Aldrich (Dorset, 
United Kingdom). Sunflower oil was purchased from ”Dija-
mant“ (Zrenjanin, Serbia). 
Concentrated phosphoric acid used for HPLC analysis 
was bought from J.T. Baker (Deventer, Netherland). Aceto-
nitrile, HPLC grade, methanol, as well as cynarin and chlo-
rogenic acid were purchased from Sigma Aldrich (Steinheim, 
Germany). Ultra pure water used for chromatography was 
prepared by means of TKA water purification system (Nie-
derelbert, Germany). 
Atorvastatin calcium standard used in the treatment was 
donated from Nobel Ilaç (Turkey).  
Herbal product used in the experiment was commercial 
artichoke leaf tincture  bought from the Institute for Medici-
nal Plant Research “Dr. Josif Pančić” (Belgrade, Serbia). 
Plant material used for tincture preparation  was dried 
primary rosette of artichoke plant. The method of extraction 
carried out by manufacturer was single percolation during 24 
hours. After that time extract was collected, left three days 
and then filtered. One part of plant material gives five parts 
of extract. Extraction was performed with mixture of ethanol 
and water (38:62, w/w). 
All other chemicals used for biochemical assays during 
the experiment were of the highest purity available and were 
obtained from Sigma Aldrich (Dorset, United Kingdom). 
Quantification of cynarin and chlorogenic acid in arti-
choke leaf tincture 
Since the manufacturer had not provided information on the 
chemical composition of the tincture, the content of cynarin and 
chlorogenic acid was determined by HPLC method described in 
Ph.Eur. 7.0 monograph for Artichoke Leaf (Cynarae folium).  
HPLC system used for experiment consisted of Agilent 
Technologies HP 1200 liquid chromatograph with binary 
pump and DAD detector (Agilent, Santa Clara, CA, SAD).  
A ZORBAX Eclipse Plus C18 Analytical (4.6 mm x 250 mm, 
5 μm) (Agilent, Santa Clara, CA, SAD) column was used for 
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chromatographic separation of the compounds. The analytes 
were eluted by a gradient mobile phase system consisting of 
mobile phase A (phosphoric acid R : water R (0.5 : 99.5 v/v)) 
and mobile phase B (phosphoric acid R : acetonitrile R (0.5 : 
99.5 v/v)). During the first minute after injection mobile phase 
was isocratic (92% mobile phase A and 8% mobile phase B). 
From the first to the twentieth minute linear change from 92% 
to 75% mobile phase A and from 8% to 25% mobile phase B 
was performed. For the next  13 minutes the ratio of mobile 
phases remained 75% mobile phase A and 25% mobile phase 
B. During the last two minutes of chromatografic run (33–35 
minutes) linear change from 75% to 0% mobile phase A and 
from 25% to 100% mobile phase B was performed. The flow 
rate was 1.2 mL/min. The column temperature was 40ºC and 
detection was performed on 330 nm. 
Reference solution of cynarin was prepared by dissol-
ving 5 mg of standard substance in 50 mL of methanol and 
further transfering 2.5 mL of prepared solution to 10 mL vo-
lumetric flask and diluting to volume with methanol. Refe-
rence solution of chlorogenic acid was prepared in the same 
way. Concentrations of cynarin and chlorogenic acid in pre-
pared standard solutions were 0.025 mg mL-1. A sample of 
the examined tincture for HPLC analysis was prepared by di-
luting 1 mL of tincture to 10 mL with the mixture of water 
and methanol (50:50, v/v). 1 mL of prepared solution was 
further diluted to 5 mL with the same diluent. 
Animals 
Male Wistar albino rats (7 weeks old, weighing 150–190 
g at the beginning of the experiment) were used for the 
experiment. Animals were obtained from the Military Medical 
Academy Farm (Belgrade, Serbia). They were housed in gro-
ups of three in a controlled environment with 12 h light and 
dark cycles and were allowed free access to food and water.  
All experimental procedures and protocols conformed 
to institutional guidelines for the care and use of animals in 
research No 5/10 (Ethics Committee of the University of 
Belgrade − Faculty of Pharmacy). 
Study protocol 
Rats were divided into five groups: the group I included 
control group rats fed with standard, normal diet (ND), and 
the remaining 4 groups (II, III, IV and V) were rats fed with 
normal pellet chow for one week, and then with 
hypercholesterolemic diet (standard pellet chow supplemen-
ted with 2% cholesterol, 3% sunflower oil and 1% sodium 
cholate) for the next ten weeks. The group II [atherogenic di-
et (AD) group] was left without treatment, while the groups 
III, IV and V consisted of atherogenic diet rats treated per os 
after four weeks without therapy, with atorvastatin (1.15 
mg/kg b.w.), artichoke leaf tincture (0.1 mL/kg b.w.), and 
their combination, respectively, for the next six weeks. This 
therapy was applied to animals with a gastric probe. Atorvas-
tatin was prepared as suspension in saline solution and artic-
hoke leaf tincture was diluted with the same solvent for 
simplicity of application.  
Doses of atorvastatin and ALTINC were chosen and 
calculated according to doses usually prescribed to humans 
and available data from experiments previously conducted 
by other researchers 14–16. It was taken that grown up person 
of average body weight 70 kg takes 80 mg of atorvastatin 
daily, which means approximately 1.15 mg per kg body 
weight. In manual published by the manufacturer of com-
mercial tincture is written that grown-up person should take 
30 drops of tincture 3 times a day which means 90 drops in 
total daily. If average body weight of grown up person is 70 
kg, that means 1.29 drops of ALTINC per kg body weight. 
For easier measurement and possible loss during treatment 
dose of ALTINC was 0.1 mL/kg b.w. These doses were 
extrapolated to experimental animals' average body weight. 
Body weights of rats were measured and doses of atorvasta-
tin and ALTINC were recalculated once a week. 
At the end of the experiment, animals from each group 
were fasted overnight, anesthetized by growing concentration of 
CO2 and blood samples were collected directly from the heart in 
test tubes containing heparine and centrifuged 3,000 rpm for 15 
min. Plasma samples were stored at -80ºC until they were 
analyzed. One part of the blood samples was hemolysed and 
erythrocyte hemolysates were kept at -80ºC until further analysis.  
The liver of the rat was immediately removed, washed in 
ice-cold saline solution and blotted. Accurately-weighed pie-
ces of tissue were minced and homogenized in nine volumes 
of 0.1 M phosphate buffer (pH 7.4), containing 1.15% KCl, 
using a polytron homogenizer. A portion of the homogenate 
was kept at -80ºC for the determination of malondialdehyde 
(MDA) and reduced glutathione (GSH) content. 
Biochemical analysis 
In plasma samples alanine aminotransferase (ALT, EC 
2.6.1.2), aspartate aminotransferase (AST, EC 2.6.1.1), total 
proteins, glucose, total cholesterol (TC), triglycerides (TG) 
and high densitylipoprotein cholesterol (HDL-C) were 
assayed by routine enzymatic methods using an ILab 300+ 
analyzer (Instrumentation Laboratory, Milan, Italy) 
and Randox Laboratories (Armdore, UK) reagents. LDL-C 
was calculated using the Friedwald equation. 
Oxidative stress parameters 
Malondialdehyde (MDA) concentrations were measu-
red using the thiobarbituric acid reactive substances 
(TBARS) assay employing the molar absorption coefficient 
of 1.56 x 105 M-1cm-1 and spectrophotometry at 535 nm 
previously described by Girotti et al. 17. Superoxidedismutase 
(SOD, EC 1.15.1.1) activity was measured according to the 
previously published method by Misra and Fridovich 18. Re-
duced glutathione (GSH) content was measured according to 
the method of Jollow et al. 19. Concentrations of sulfhydryl 
(SH) groups in plasma and erythrocytes were determined 
using 0.2 mmol/L 5.5′-dithiobis (2-nitrobenzoic acid) 
(DTNB) reported by Ellman 20. Plasma pro-oxidant-anti-
oxidant balance (PAB) was measured according to a 
previously published method 21. Rates of paraoxonase 
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(PON1, EC 3.1.8.1) activity towards diazoxon were measu-
red spectrophotometrically in plasma according to the met-
hod described by Richter and Furlong 22. Diazoxon was pur-
chased from Chem Service (West Chester, PA, USA). The 
activities are reported as IU/L. 
Abdominal aorta wall thickness examination 
For light microscopic examination, the lower portions of 
the abdominal aorta were dissected, formaldehyde-fixed and 
routinely embedded in paraffin. To distinguish between mus-
cle cells and extracellular components of the aortic wall, 5 µm 
thick, the transversal sections of the aorta were rehydrated and 
stained according to the Azan trichrome staining method. Stai-
ned sections were analyzed microscopically (DMLB light mic-
roscope, Leica Microsystems, Mannheim, Germany). Wall 
thickness was measured using Image J software (NIH, Bethes-
da, Maryland, USA) by random selection of ten positions on 
the sections from every animal. 
Statistical analysis 
The characteristics of the study populations are presen-
ted as means ± standard deviations. Studied variables were 
compared using ANOVA with Tukey-Snedecor test as a post 
hoc analysis. Statistical analyses were performed using 
PASW® Statistic version 18 (Chicago, Illinois, USA) and 
Microsoft® Office Excel 2007. A value of p less than 0.05 
was considered statistically significant. 
Results 
Content of cynarin and chlorogenic acid in artichoke 
leaf tincture 
The determined content of both, cynarin and chloroge-
nic acid in investigated tincture was 0.2%. 
Biochemical parameters 
Table 1 indicates basic biochemical and lipid parame-
ters, as well as animal body weight after six weeks of treat-
ment. Results showed an increased concentration of liver 
enzymes (AST and ALT) in the groups on the atherogenic 
diet and atorvastatin (alone or in combination with AL-
TINC). The group that received only ALTINC showed the 
same level of liver enzyme activities as normally fed rats.  
Lipid parameter concentrations were significantly higher 
in all the groups fed with atherogenic diet, except HDL-C con-
centrations which were similar in all the experimental groups 
and triglycerides which were lower in the groups on atheroge-
nic diet. The group on atorvastatin treatment showed the 
lowest concentration, although with no statistical significance.  
Abdominal aorta examination 
The atherogenic diet led to a significant increase in ab-
dominal aorta wall thickness comparing to rats fed with 
normal diet (Figure 1). It was found that all types of therapy 
had beneficial effect, but only the combination of atorvastatin  
and ALTINC decreased the thickness of the aortic wall with a 
statistically significant difference comparing to rats fed with 
atherogenic diet (p < 0.001) (Figure 1). Microscopic analysis 
of abdominal aorta (Figure 2A) revealed proper organization 
of muscular layers and elastic laminas maintained in most gro-
ups. Exceptions were the groups on AD and the group on 
AD + Ator (Figures 2B and C), where plaques were visible, 
distorting the proper organization of aortic wall tunica media. 
Determination of oxidative stress and antioxidative pa-
rameters in liver tissue 
To assess tissue oxidative status upon challenge with 
the atherogenic diet, as well as after antihyperlipidemic statin 
drug treatment, and under the influence of artichoke leaf 
 
Table 1 
Effect of atorvastatin (1.15 mg/kg body weight) and artichoke leaf tincture  
(ALTINC) (0.1 mL/kg body weight) treatment on general biochemical and lipid parameters after treatment 
Parameter ND AD AD + Ator AD + ALTINC AD + Ator + ALTINC p 
Weight gain (% comparing 
to weight at the beginning 
of the experiment) 
154 ± 21 196 ± 31a 187 ± 18a 175 ± 27 191 ± 18a ≤ 0.05 
ALT (IU) 39.5 ± 7.0 51.8 ± 12.8 56.2 ± 11.0 47.5 ± 12.2 64.3 ± 10.5 ≤ 0.01 
AST (IU) 122.8 ± 39.6 167.2 ± 19.1 205.4 ± 35.7aa 127.5 ± 52.8c 169.8 ± 19.3 ≤ 0.01 
tCHOL (mmol/L) 1.45 ± 0.19 2.96 ± 0.49 3.67 ± 1.75 4.48 ± 1.39a 3.80 ± 1.66 ≤ 0.01 
LDL (mmol/L) 0.64 ± 0.21 2.28 ± 0.53 3.06 ± 1.72 3.83 ± 1.45a 3.15 ± 1.67 ≤ 0.01 
HDL (mmol/L) 0.478 ± 0.057 0.446 ± 0.108 0.428 ± 0.064 0.442 ± 0.092 0.455 ± 0.075 0.86 
nonHDL (mmol/L) 0.97 ± 0.14 2.51 ± 0.49 3.24 ± 1.74 3.49 ± 1.64 3.34 ± 1.68 ≤ 0.05 
TG (mmol/L) 0.737 ± 0.205 0.508 ± 0.114 0.382 ± 0.065 0.455 ± 0.126 0.422 ± 0.137 ≤ 0.001 
TP (g/L) 70.8 ± 7.8 71.5 ± 4.7 72.1 ± 1.4 69.2 ± 2.3 69.9 ± 1.6 0.780 
GLU (mmol/L) 7.3 ± 1.5 7.1 ± 1.8 6.6 ± 0.8 7.8 ± 1.1 8.3 ± 2.0 0.362 
ALT – alanine aminotransferase; AST – aspartate aminotransferase; tCHOL – total cholesterol concentration; LDL – concentration of 
cholesterol contained in low density lipoproteins; HDL – concentration of cholesterol contained in high density lipoproteins; nonHDL – 
concentration of cholesterol apart from cholesterol contained in high density lipoproteins; TG – concentration of triglycerides; TP – 
concentration of total proteins; GLU – concentration of glucose; ND – rats fed with normal diet; AD – rats fed with atherogenic diet, AD + Ator – 
rats fed with atherogenic diet treated with atorvastatin; AD + Ator + ALTINC – rats fed with atherogenic diet treated with atorvastatin and 
artichoke leaf tincture combination; AD + ALTINC – rats fed with atherogenic diet treated with artichoke leaf tincture. 
Note: The results are given as mean ± standard deviation. 
> p − values in the last column according to ANOVA; p − values according to post-hoc Tukey-Snedecor test: a p < 0.05, aa p < 0.01 vs ND; 
cp < 0.05 vs AD + Ator. 
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Fig. 1 − Average vaules of abdominal aorta wall thickness (μm) after six weeks of treatment. 
ND – normal diet; AD – atherogenic diet; AD + Ator – atherogenic diet with atorvastatin treatment, AD + Ator + 
ALTINC – atherogenic diet with atorvastatin and artichoke leaf tincture (ALTINC) treatment; AD + ALTINC – athero-
genic diet with artichoke leaf tincture treatment. 
Each bar represents the mean ± SEM (n = 6). Statistical comparison was performed using ANOVA with Tukey-Snedecor 
test as post hoc analysis. The stars show a p value between groups connected with lines; ***p < 0.001. 
 
 
Fig. 2 − Representative photomicrographs of cross-sections through the abdominal aorta. 
A – normal diet; B – atherogenic diet; C – atherogenic diet with atorvastatin treatment; D – atherogenic diet with atorvas-
tatin and artichoke leaf tincture treatment; E – atherogenic diet with artichoke leaf tincture treatment. 
The differences in tunica media thickness among the groups are observed. Also, in tunica media of rats on atherogenic diet 
and rats on atherogenic diet treated with atorvastatin, plaques are visible (spots marked area), leading to the distortion of 
proper organization of muscle layers and elastic laminas of tunica media (Azan trichrome staining, scale bars 50 μm). 
tincture treatment we performed liver tissue oxidative stress 
analysis, i.e. MDA and GSH determination. 
Malondialdehyde increased after the atherogenic diet. 
The therapy slightly lowered MDA, comparing with the 
group that was on the atherogenic diet, but without statisti-
cal significance (Figure 3). Our results showed a decrease 
in liver tissue GSH concentration after the atherogenic diet. 
Treatment with atorvastatin, ALTINC and the combination 
of both increased the concentration of GSH several fold 
(Figures 2D and 2E). Reduced glutathione was highest in 
the group that received ALTINC, far above GSH for ani-
mals on the ND (p < 0.001).  
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Determination of oxidative stress and antioxidative pa-
rameters in plasma 
Oxidative stress and antioxidative parameters were de-
termined in plasma to estimate the oxidative stress changes 
in circulation (Table 2). 
Malondialdehyde increased in all the treated groups 
(p  0.05 compared with the ND group). 
Prooxidative – antioxidative balance (PAB) value was 
higher in the groups on the AD and atorvastatin treatment re-
gardless of whether it was administered alone or in combina-
tion with ALTINC (p < 0.01) compared with the ND group. 
The group that received only ALTINC showed values com-
parable with the group on the ND. Superoxide dismutase 
(SOD) activity was slightly lower in the group that was on 
the atherogenic diet. The therapy increased SOD activity 
(statistically significant effect of ALTINC, comparing with 
the groups on normal and atherogenic diets). 
We found increased concentrations of total SH groups 
in all experimental groups compared with the ND group, alt-
hough this increase was not statistically significant. The con-
centration of GSH significantly fell under the influence of 
AD. Atorvastatin and the combined treatment failed to incre-
ase GSH, but the ALTINC increased GSH significantly. 
PON1 activity significantly decreased in the group gi-
ven atherogenic diet. The therapy with either atorvastatin or 
ALTINC alone has no effect on the activity of paraoxonase. 
Only the combination of atorvastatin and ALTINC was able 
to maintain PON1 activity at baseline levels.  
Determination of oxidative stress and antioxidative pa-
rameters in erythrocyte hemolysate 
Oxidative stress and antioxidative parameters were mea-
sured in erythrocyte hemolysate to determine the oxidative-
stress changes in blood cells (Table 3). There was no difference  
 
Fig. 3 − Oxidative stress status in liver tissue after six weeks of treatment. 
a – glutathione (GSH) concentration; b – melondialdehyde (MDA) concentration; ND – normal diet; AD – atherogenic diet; AD 
+ Ator – atherogenic diet with atorvastatin treatment; AD + Ator + ALTINC – atherogenic diet with atorvastatin and artichoke 
leaf tinctura treatment; AD + ALTINC – atherogenic diet with artichoke leaf tinctura treatment. 
Each bar represents the mean ± SEM (n = 6). Statistical comparison was performed using ANOVA with Tukey-Snedecor 
test as post hoc analysis. The stars show a p value between groups connected with lines. ***p < 0.001. 
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in MDA levels and concentration of SH groups between all 
examined groups (p > 0.05). 
SOD activity was significantly higher (p < 0.05) in the 
groups on the atherogenic diet regardless of the therapy. 
SOD activity was highest in the groups that had received 
ALTINC as treatment (alone or in combination with atorvas-
tatin). All the groups receiving therapy showed higher GSH 
concentrations. The treatment with ALTINC led to the hig-
hest level of GSH (p < 0.01 comparing with the normal diet; 
p < 0.05 comparing with the atherogenic diet). 
Discussion 
Cholesterol feeding has often been used in experimental 
animals to study the pathogenesis of atherosclerosis. We sup-
plemented a rat commercial diet with cholesterol, sodium chola-
te and sunlower oil as atherogenic compounds. Sodium cholate, 
which has an inhibitory action on hepatic cholesterol 7-α 
hydroxylase (EC 1.14.13.17) activity, is known to improve cho-
lesterol absorption because of its emulsifying properties 23. 
It is well-known that oxidative stress is a mechanism 
underlying pathogenesis of atherosclerosis. Our findings, 
which are in accordance with previous studies 23, 24, show that 
hypercholesterolemia disturbs PAB in favor of prooxidation in 
liver tissue (Figure 2). 
Atorvastatin is the first choice drug for reducing lipids 
in hypercholesterolemic patients. Several studies have de-
monstrated that atorvastatin has no influence in high HDL-C 
concentration 5. Atorvastatin has been found to exert benefi-
cial cardiovascular effects independent of its ability to lower 
lipid amounts, possibly due to its antioxidant properties 1, 4, 13. 
The mechanism involved in this phenomenon may be the 
ability of atorvastatin to reduce the production of reactive 
oxygen species 1. Also, atorvastatin may play a role in pro-
tecting low density lipoprotein (LDL) and HDL from 
oxidation by increasing antioxidant activity of the HDL-
associated enzyme PON1 4, 5. 
Different types of extracts of artichoke leaf have been 
considered to show antiatherogenic properties. It is reported 
that aqueous extract of artichoke leaf inhibits cholesterol 
biosynthesis in hepatocytes, decreases the oxidation of LDL, 
modulate endothelial functions and has choleretic activity 16. 
Studies clearly show that cynarin is the main dicaffeoylquinic 
acid and chlorogenic acid is the major monocaffeoyilquinic 
acid, whereas luteolin-7-O-glucoside is the major flavonoid. 
Both caffeoylquinic acids and flavonoids present in artichoke 
extracts are considered to be responsible for its antiatherogenic 
actions. Llorach at al. 7 investigated different artichoke 
byproducts (raw artichoke, blanched artichoke and artichoke 
blanching waters). They extracted phenolic constituents 
(expressed as caffeic acid derivatives) with methanol and 
water. Both, methanol and water extracts from artichoke 
byproducts showed a high free radical scavenging activity as 
well as capacity to inhibit lipid peroxidation. Gebhardt and 
Fausel 2 performed in vitro tests and exposed cultured rat 
hepatocytes to oxidation and cytotoxicity with tert-butyl 
hydroperoxide in order to characterize the antioxidative and 
hepatoprotective properties of aqueous artichoke extracts. 
They added aqueous artichoke extracts to rat hepatocytes prior 
or simultaneously with tert-butylhydroperoxide. In vitro studi-
es of Gebhardt and Fausel 12 have provided evidence that the 
antioxidant potential of aqueous extract of artichoke leaves is 
dependent on radical scavenging and metal ion chelating ef-
fects of its constituents such as cynarin, chlorogenic acid and 
flavonoids. However, pure constituents of artichoke leaf have 
been shown to produce less inhibitory activity on free radical 
production than any type of extract 11, 12. 
In the present study the cholesterol rich diet led to an inc-
rease in the concentration of several lipid parameters (total 
cholesterol, LDL-C, nonHDL-C), though not all: triglycerides 
and HDL-C were unaffected. The therapy with atorvastatin 
and ALTINC did not reduce the concentration of lipid parame-
ters, which was also noticed by other researchers 25 and which 
could be explained, at least in part, with supremacy of diet-
induced lipids. Also, this therapy did not influence HDL-C 
which is consistent with the published data 4, 5.  
Measurements of the abdominal aorta wall thickness have 
proven useful in predicting cardiovascular disease risk 26. Incre-
ase in the thickness of the abdominal aorta wall in this study in-
dicates the damage of the wall due to plaque formation in athe-
rogenesis. Intake of AD led to the thickening of the aortic wall 
(Figure 1), as well as to plaque formation (Figure 2). Relatively 
short atorvastatin treatment failed to restore the aortic wall as 
shown in Figures 1 and 2. Treatment with ALTINC (alone and 
especially in combination with atorvastatin) managed to reduce 
abdominal aorta wall thickness and reversed plaque formed du-
ring atherogenesis. More favorable effect of ALTINC compa-
ring to atorvastatin prove that ALTINC is better antioxidant. 
The effect of combination of atorvastatin and ALTINC shows 
that these two treatments have an additive effect. 
Liver transaminases (ALT and AST) in the 
hypercholesterolemic rats were higher than in normal ani-
mals, which may be attributed to the injury of liver tissue 27. 
We have noticed that treatment with atorvastatin in current 
work led to further increase in plasma transaminase levels. 
Previous research has shown that atorvastatin can induce a 
mild increase in ALT and AST activity. Long-term therapy 
in most cases does not lead to liver damage, although there 
are rare cases of acute hepatotoxicity induced by atorvastatin 27. 
The therapy with ALTINC decreased plasma transaminase 
activity demonstrating its hepatoprotective effect, which is in 
accordance with previous studies 12.  
Lipid peroxidation is a well-established mechanism of 
cellular injury and measurement of MDA is widely used as 
an indicator of oxidative stress in cells and tissues. Rats fed 
with atherogenic diet in this study showed increase in MDA 
concentration because of oxidative stress that occurred in at-
herogenesis 23. This therapy did not reduce plasma MDA le-
vel as expected, presumably because the very concentrated 
cholesterol diet led to advanced lipid peroxidation, which 
probably could not be prevented by the antioxidant activity 
of atorvastatin and ALTINC during the relatively short time 
of the experiment. On the other side, all types of therapy led 
to a significant reduction in the concentration of MDA in li-
ver tissue comparing to the group on atherogenic diet, indica-
ting that atorvastatin and aqueous-ethanolic artichoke leaf 
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extract have antioxidant effects, as shown by previous rese-
archers 1, 4, 12. The combination of ALTINC and atorvastatin 
showed an even stronger effect in preventing 
lipoperoxidation (Table 2). MDA levels in erythrocyte 
hemolysate did not differ significantly among the groups, but 
positive effects of every type of therapy was noticed. The 
therapy with ALTINC had especially beneficial effects as in 
liver tissue. 
Prooxidative-antioxidative balance was determined 
only in plasma and it increased upon atherogenic diet due to 
oxidative stress that occured. Atorvastatin therapy (alone or 
in combination with ALTINC) did not lead to a decrease of 
PAB as expected. Only therapy with ALTINC decreased 
PAB, which demonstrated antioxidative action of the plant 
extract (Table 3). 
Our results show that any form of therapy increased the 
concentration of SH groups that play a role in neutralizing 
free radicals in plasma, as expected. The most effective trea-
tment was with ALTINC. Changes in reduced glutathione 
levels were the same in all sample types (Tables 2 and 3). 
Atherogenic diet decreased the level of GSH, which was 
presumably used in neutralizing free radicals formed during 
the process of atherogenesis. The treatments in our 
experiment regenerated spent glutathione. ALTINC showed 
the strongest effect (Table 2) indicating strong antioxidant 
activity of some consituents, such as flavonoids and 
hydroxycinnamic acids to be effective hydrogen donors and 
metal chelators as shown by Zapolska-Downar et al. 28 who 
tested aqueous and ethanolic extracts of artichoke plant. Caf-
feic and chlorogenic acid have also been reported to stimula-
te hydroxyl radical formation and to have pro-oxidant 
activity on Cu2+-induced LDL oxidation 28. It has been de-
monstrated that aqueous and ethanolic extracts of artichoke 
plant protect LDL against oxidative modification in vitro 11. 
Gebhardt and Fausel 12 have reported that aqueous extract of 
artichoke leaf inhibits the production of MDA induced by 
exposure of cultured hepatocytes to t-butylhydroperoxide (t-
BHP). According to them, the observed antioxidative poten-
tial can be attributed to some well-known components of ar-
tichoke leaf extract, although their action cannot account for 
the full potency of the extract. In our study, antioxidant ef-
fect of ALTINC was obvious, especially when used alone in 
the treatment. Atorvastatin is extensively metabolized in the 
liver under the influence of the enzyme CP3A4 and therefore 
combinations in which it is used must be carefully selected 
since a lot of drugs is metabolized by the same enzymes 29. 
Constituents of artichoke leaf tincture (cynarin and chloro-
genic acid) are metabolized in the same manner. So, a possi-
ble interaction between ALTINC and atorvastatin could be 
on the metabolism level. 
Paraoxonase has emerged as the component of HDL 
most likely to explain its ability to metabolize lipid peroxides 
and to prevent their accumulation in LDL. Paraoxonase 
immunoreactivity is known to be increasingly present in the 
arterial wall as atheroma advances 30. Protection of LDL and 
HDL from oxidation is probably related to PON’s ability to 
hydrolyze some oxidized phospholipids and/or cholesteryl 
linoleate hydroperoxides which are present in oxidized LDL. 
Other studies show that during LDL oxidation in the presen-
ce of PON1, the enzyme is partially inactivated 31. This ef-
fect could be related to displacement of calcium ions (which 
are required for PON arylesterase/paraoxonase activities) by 
copper ion (in the copper ion oxidative system). In the free 
radical oxidation system, as well as in the copper ion system, 
free radicals formed during lipid peroxidation can also inac-
tivate PON 32. Our results in plasma samples confirm that 
PON1 is consumed during atherogenesis so its levels are 
lowest in the group on an atherogenic diet. Antioxidants in 
the treatment of atherosclerosis prevent oxidation of LDL 
cholesterol and thus preserve PON1 activity 32. In our study, 
only ALTINC show this effect. Atorvastatin treatment has no 
significant effect on this enzyme activity which may indicate 
lower antioxidant potential of atorvastatin.  
An increased antioxidant activity of SOD in 
erythrocytes was also found by Küçükgergin et al. 33 after 
treatment with artichoke dry extract dissolved in water which 
confirmed antioxidant properties of artichoke plant. 
Conclusion 
Treatment with artichoke leaf tincture and atorvastatin 
shows beneficial effects on oxidative stress parameters, but 
has little influence on basic lipid parameters. Investigated ar-
tichoke leaf tincture shows even better results in oxidative 
stress reduction than low-dose atorvastatin which is a 
widely-prescribed drug in the treatment of atherosclerosis. 
All the determined parameters show that artichoke leaf tinc-
ture (alone or in combination with atorvastatin) is very po-
tent antioxidant in applied doses. Effects of specific constitu-
ents of ALTINC on oxidative damage should be further in-
vestigated. Since atorvastatin and constituents of ALTINC 
probably have different mechanisms of action, simultaneous 
use of both therapies could be beneficial but should be furt-
her investigated since our results show that ALTINC is less 
effective when used in combination with atorvastatin.  
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